MaxQ Medical, a Sunnyvale, California-based health-tech startup, has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with existing investor Hillside Capital also participating. The company will use the proceeds to expand its team and advance clinical evaluations already underway. Its investigational system combines transurethral imaging with tissue-selective therapy in a single outpatient procedure, initially targeting benign prostatic hyperplasia (BPH), a noncancerous enlargement affecting an estimated 40 million men in the U.S. MaxQ aims to offer the durability of resective treatments such as TURP with side effects more comparable to minimally invasive options, while preserving the urethra and giving urologists visibility of the prostate during treatment. The platform is not commercially available in the United States and could later be expanded to focal prostate cancer therapy, biopsy and tumor mapping. MaxQ is the first spinout of Orchard Ultrasound Innovation, which commercializes Stanford University semiconductor ultrasound research led by Professor Pierre Khuri-Yakub.